Kalvista Pharmaceuticals Inc (NASDAQ:KALV) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 877,600 shares, a growth of 11.3% from the December 15th total of 788,700 shares. Based on an average daily volume of 154,400 shares, the days-to-cover ratio is currently 5.7 days. Approximately 7.0% of the company’s stock are short sold.
Shares of KALV traded up $1.02 during mid-day trading on Thursday, hitting $18.00. 49,008 shares of the company traded hands, compared to its average volume of 113,194. The company has a market capitalization of $309.53 million, a PE ratio of -13.04 and a beta of 2.22. The company has a quick ratio of 10.30, a current ratio of 10.31 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average of $16.13 and a 200 day moving average of $14.89. Kalvista Pharmaceuticals has a 1-year low of $9.86 and a 1-year high of $34.92.
Kalvista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Tuesday, December 3rd. The specialty pharmaceutical company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.22. The company had revenue of $3.92 million during the quarter, compared to analysts’ expectations of $3.23 million. Kalvista Pharmaceuticals had a negative net margin of 182.37% and a negative return on equity of 25.70%. As a group, research analysts expect that Kalvista Pharmaceuticals will post -1.63 EPS for the current fiscal year.
In other news, insider Christopher Yea sold 3,010 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $17.05, for a total value of $51,320.50. Following the sale, the insider now directly owns 83,168 shares in the company, valued at approximately $1,418,014.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas Andrew Crockett sold 5,400 shares of Kalvista Pharmaceuticals stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $17.06, for a total transaction of $92,124.00. Following the completion of the transaction, the chief executive officer now directly owns 248,320 shares in the company, valued at approximately $4,236,339.20. The disclosure for this sale can be found here. Insiders sold 10,010 shares of company stock valued at $170,720 over the last quarter. 21.60% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new stake in shares of Kalvista Pharmaceuticals during the second quarter valued at $42,000. Tower Research Capital LLC TRC raised its position in Kalvista Pharmaceuticals by 1,919.3% during the third quarter. Tower Research Capital LLC TRC now owns 3,877 shares of the specialty pharmaceutical company’s stock valued at $45,000 after acquiring an additional 3,685 shares in the last quarter. Orbimed Advisors LLC acquired a new position in Kalvista Pharmaceuticals in the third quarter valued at approximately $449,000. Citadel Advisors LLC acquired a new position in Kalvista Pharmaceuticals in the second quarter valued at approximately $467,000. Finally, Algert Global LLC boosted its position in Kalvista Pharmaceuticals by 48.7% in the 2nd quarter. Algert Global LLC now owns 24,667 shares of the specialty pharmaceutical company’s stock worth $546,000 after purchasing an additional 8,076 shares in the last quarter. 82.21% of the stock is owned by institutional investors and hedge funds.
Several brokerages have weighed in on KALV. Zacks Investment Research upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, December 6th. ValuEngine upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. BidaskClub cut Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 10th. Finally, Needham & Company LLC dropped their target price on Kalvista Pharmaceuticals from $35.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $27.20.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Story: Penny Stocks
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.